US Brand Name(s): Ceflatonin, Synribo
Use of Omacetaxine Mepesuccinate in Cancer Treatment
Omacetaxine mepesuccinate has authorization to treat the following conditions:
Chronic myelogenous leukaemia is a kind of cancer that affects the blood cells. It’s in use with individuals with chronic phase or accelerated phase illness who can’t have treatment with tyrosine kinase inhibitors or who have grown worse after taking at least two of them.
Omacetaxine mepesuccinate is also under research for use in the treatment of various cancers.
Detailed scientific definition- Definition from the NCI Drug Dictionary
Omacetaxine Mepesuccinate – MedlinePlus Information A summary of key facts regarding this medication in layman’s terms, which may contain the following:
cautions about this medicine, what it’s in use for and how to use it, what you should tell your doctor before taking it, what you should know about it before using it, other drugs that might interact with it, and possible negative effects
Drugs are frequently under investigation to see whether they can assist treat or prevent conditions other than those for which they have authorization. Only authorized uses of the medication come under this patient information leaflet. Much of the material, though, might also apply to authorized uses that are under investigation.
